Show simple item record

dc.contributor.authorİnci, Sevim Berrinen_US
dc.contributor.authorİpçi, Melisen_US
dc.contributor.authorErcan, Eyüp Sabrien_US
dc.date.accessioned2022-04-05T19:39:16Z
dc.date.available2022-04-05T19:39:16Z
dc.date.issued2022-03-06
dc.identifier.citationİnci, S. B., İpçi, M. & Ercan, E. S. (2022). Methylphenidate significantly improves neurocognitive impairments in children with ADHD. Psychiatry Research, 311, 1-8. doi:10.1016/j.psychres.2022.114492en_US
dc.identifier.issn0165-1781
dc.identifier.issn1872-7123
dc.identifier.otherWOS:000793396100010
dc.identifier.urihttps://hdl.handle.net/11729/3859
dc.identifier.urihttp://dx.doi.org/10.1016/j.psychres.2022.114492
dc.descriptionPubMed ID: 35306379
dc.description.abstractThis study aimed to investigate the effects of methylphenidate (MPH) on scores on a neurocognitive test battery for individuals with various presentations of attention deficit/hyperactivity disorder (ADHD) and the effect of comorbidities on executive function. This study included 861 children and adolescents aged 7–17 years who were diagnosed with ADHD according to DSM-V criteria. The CNS Vital Signs Battery was utilized to compare the neuropsychological characteristics and MPH treatment responses of patients with predominantly inattentive (ADHD-I) and combined (ADHD-C) presentations of ADHD. Before MPH administration, a statistically significant difference was observed between groups only for complex attention. In addition, the overall prevalence rate of psychiatric comorbidities was 45.5%, and no statistically significant differences were found in the ADHD-I group pre- versus post-MPH administration. Prior to the administration of MPH, statistically significant differences were observed within the ADHD-C group between those with or without comorbidities. However, after MPH administration, these differences between the groups disappeared. The effects of MPH on improving scores on neuropsychological subtests were similar between the groups with different presentations of ADHD. Additionally, MPH treatment was effective despite the presence of comorbidities.en_US
dc.language.isoengen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.isversionof10.1016/j.psychres.2022.114492
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectADHDen_US
dc.subjectComorbidityen_US
dc.subjectMethylphenidateen_US
dc.subjectNeurocognitive test batteryen_US
dc.subjectPresentations of ADHDen_US
dc.subjectAttention-deficit/Hyperactivity disorderen_US
dc.subjectDeficit hyperactivity disorderen_US
dc.subjectPerformance-test performanceen_US
dc.subjectResponse-inhibitionen_US
dc.subjectExecutive functionsen_US
dc.subjectTest batteryen_US
dc.subjectSubtypesen_US
dc.subjectBoysen_US
dc.subjectAdolescentsen_US
dc.titleMethylphenidate significantly improves neurocognitive impairments in children with ADHDen_US
dc.typearticleen_US
dc.description.versionPublisher's Versionen_US
dc.relation.journalPsychiatry Researchen_US
dc.contributor.departmentIşık Üniversitesi, Fen Edebiyat Fakültesi, Psikoloji Bölümüen_US
dc.contributor.departmentIşık University, Faculty of Arts and Sciences, Department of Psychologyen_US
dc.contributor.authorID0000-0001-8776-3825
dc.identifier.volume311
dc.identifier.startpage1
dc.identifier.endpage8
dc.peerreviewedYesen_US
dc.publicationstatusPublisheden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorİnci, Sevim Berrinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record